Triflunex 500 mg/200 mg/10 mg pulveris iekšķīgi lietojama šķīduma pagatavošanai Lativia - Kilatvia - Zāļu valsts aģentūra

triflunex 500 mg/200 mg/10 mg pulveris iekšķīgi lietojama šķīduma pagatavošanai

wick pharma, germany - paracetamolum, guaifenesinum, phenylephrini hydrochloridum - pulveris iekšķīgi lietojama šķīduma pagatavošanai - 500 mg/200 mg/10 mg

Dioppex 1000 mg/12,2 mg pulveris iekšķīgi lietojama šķīduma pagatavošanai Lativia - Kilatvia - Zāļu valsts aģentūra

dioppex 1000 mg/12,2 mg pulveris iekšķīgi lietojama šķīduma pagatavošanai

wick pharma, germany - paracetamolum, phenylephrini hydrochloridum - pulveris iekšķīgi lietojama šķīduma pagatavošanai - 1000 mg/12,2 mg

Sinex 0,5 mg/ml deguna aerosols, šķīdums Lativia - Kilatvia - Zāļu valsts aģentūra

sinex 0,5 mg/ml deguna aerosols, šķīdums

wick pharma, germany - oksimetazolīna hidrohlorīds - deguna aerosols, šķīdums - 0,5 mg/ml

ExPress Essentials cits, Cietā želatīna kapsula Lativia - Kilatvia - Pārtikas un veterinārais dienests, Zemkopības ministrija

express essentials cits, cietā želatīna kapsula

spēka pasaule, biedrība 40008062117 raiņa ielā 3, valmiera, lv-4201, latvija - cits, cietā želatīna kapsula - cits - pārtikas produkts, kas paredzēts intensīvas muskuļu piepūles gadījumos, īpaši sportistiem

Memantine LEK Umoja wa Ulaya - Kilatvia - EMA (European Medicines Agency)

memantine lek

pharmathen s.a. - memantīna hidrohlorīds - alcheimera slimība - psychoanaleptics, , citas anti-demenci zāles - pacientiem ar vidēji smagu vai smagu alcheimera slimību ārstēšana.

Comirnaty Umoja wa Ulaya - Kilatvia - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcīnas - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. izmantojot šo vakcīnu, kas būtu saskaņā ar oficiālās rekomendācijas.

Clopidogrel/Acetylsalicylic acid Teva Umoja wa Ulaya - Kilatvia - EMA (European Medicines Agency)

clopidogrel/acetylsalicylic acid teva

teva pharma b.v. - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - combinations - clopidogrel/acetylsalicylic acid teva indicēts aterotrombotiskām notikumiem pieaugušiem pacientiem, kas jau veic gan clopidogrel acetilsalicilskābes (asa) profilakse. klopidogrelu/acetilsalicilskābe teva ir fiksētas devas kombinācija zāles, turpinot terapiju:bez st segmenta pacēluma akūtu koronāro sindromu (nestabila stenokardija vai ne‑q zoba miokarda infarkts), tostarp pacientiem, kam veic stentu izvietošana pēc perkutānas koronāras interventionst segmenta pacēlums, akūts miokarda infarkts, medicīniski ārstēti pacienti saņemt trombolītiskā terapija.

Atorvastatin Teva 40 mg apvalkotās tabletes Lativia - Kilatvia - Zāļu valsts aģentūra

atorvastatin teva 40 mg apvalkotās tabletes

teva pharma b.v., netherlands - atorvastatīns - apvalkotā tablete - 40 mg

Atorvastatin Teva 10 mg apvalkotās tabletes Lativia - Kilatvia - Zāļu valsts aģentūra

atorvastatin teva 10 mg apvalkotās tabletes

teva pharma b.v., netherlands - atorvastatīns - apvalkotā tablete - 10 mg

Atorvastatin Teva 20 mg apvalkotās tabletes Lativia - Kilatvia - Zāļu valsts aģentūra

atorvastatin teva 20 mg apvalkotās tabletes

teva pharma b.v., netherlands - atorvastatīns - apvalkotā tablete - 20 mg